Navigation Links
Dendreon Reports Third Quarter 2007 Financial Results
Date:11/15/2007

- Management Will Host Conference Call at 1:30 PM ET -

SEATTLE, Nov. 15 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2007. Revenue for the third quarter of 2007 was $112,000 compared to $84,000 for the quarter ended September 30, 2006. Revenue for the nine months ended September 30, 2007 was $715,000 compared to $187,000 for the nine months ended September 30, 2006.

Dendreon's total operating expenses for the third quarter of 2007 were $19.8 million compared to $21.7 million in 2006. Dendreon's total operating expenses for the nine months ended September 30, 2007 were $75.2 million compared to $73.6 million for the same period in 2006.

The net loss for the quarter ended September 30, 2007 was $19.2 million, or $0.23 per share, compared to a net loss of $20.7 million, or $0.29 per share, for the quarter ended September 30, 2006. The net loss for the nine months ended September 30, 2007 was $72.3 million, or $0.88 per share, compared to $70.2 million, or $0.98 per share for the nine months ended September 30, 2006.

Cash, cash equivalents and short-term and long-term investments at September 30, 2007 totaled $138.8 million compared to $121.3 million at December 31, 2006.

Recent Highlights:

-- Completed enrollment of over 500 patients in the Phase 3 IMPACT

(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as

D9902B) clinical trial of PROVENGE(R) (sipuleucel-T). Dendreon

received confirmation that the FDA will accept either a positive

interim or positive final analysis of overall survival from the IMPACT

study to amend the Biologics License App
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Wyle ... Fully Integrated Lifecycle Mission Support Services (FILMSS) contract ... (NASA). Under the terms of the contract, Wyle ... at Moffett Field, Calif. In particular, Wyle will ... flight development projects on the International Space Station ...
(Date:7/30/2014)... STONY BROOK, NY (PRWEB) July 30, 2014 ... (OTCQB: APDN), (Twitter: @APDN), a biotechnology firm that provides ... Dr. Michael E. Hogan, Ph.D. Vice President of Life ... in mid-September. , Dr. Hogan will lead ... to form business relationships with biotech and healthcare customers, ...
(Date:7/30/2014)... PA (PRWEB) July 30, 2014 Vycom ... family of products, designed to meet Factory Mutual (FM) ... equipment materials such as wet benches, process tools, fume ... worker safety and damage to semiconductor wafers used in ... provides a flame-retardant PVC solution with excellent workability and ...
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... GAMMAGARD LIQUID and GAMMAGARD S/D, [Immune Globulin Intravenous ... Ill., Aug. 22 Baxter International,Inc. (NYSE: ... GARDian, an innovative,program that helps provide continued access ... [Immune Globulin Intravenous (Human)],(IGIV). IGIV products like GAMMAGARD ...
... 22 ATS Medical, Inc.,(Nasdaq: ATSI ), ... services, today announced that the US Food and ... begin marketing,additional sizes of its line of ATS ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) Michael Dale, Chairman and Chief ...
... New Ballot Initiative to Pursue Cures for Patients, ... without involving controversial Human Cloning, WASHINGTON, Aug. 22 ... ensure that taxpayer funds,support cures for patients, without involving human ... issued the,following statement on the new initiative, Cures Without Cloning. ...
Cached Biology Technology:Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 2Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 3Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 4Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 5Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 6Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 7Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 8Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 9ATS Medical Expands Open Pivot Heart Valve Offerings 2
(Date:7/30/2014)... by the Red Queen in Lewis Carroll,s Through ... Illinois and National University of Singapore improved a ... evolve over decades to millions of years. , ... for competition, incorporates the "Red Queen Effect," an ... the 1970s, which suggests that organisms must constantly ...
(Date:7/30/2014)... octopus protected and tended her eggs until they hatched ... 30, 2014 in the open-access journal PLOS ONE ... Institute and colleagues. , Octopuses typically have a single ... and take care of their fertilized eggs until they ... 1 to 3 months, but little is known about ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... are closing in on finding an effective bait to ... beetle, which is now killing not only lodgepole pine ... and Canada Research Chair in Forest Entomology in the ... investigating pheromones emitted by the pest in North America,s ...
... of New England (Australia) and the Royal Botanic Gardens ... species of sedge from south-western Tasmania. A small clumping ... mountains including Mount Field and Mount Sprent. It is ... essentially restricted to alpine vegetation. At less than seven ...
... professor is developing a comprehensive data system that can ... by providing them with access to chemical toxicity information. ... is building the "automated profiling system" from existing bioassay ... profiles can help scientists who are seeking information on ...
Cached Biology News:Bait research focused on outsmarting destructive beetle 2Tasmania home to first alpine sword-sedge 2Toxicity database under development at Rutgers-Camden 2